https://orcid.org/0000-0001-9750-0041
References
- UK Electronic Medicines Compendium (emc). Summary of product characteristic of misoprostol (cytotec) 200 microgram tablet (Pfizer limited). Available from: https://www.medicines.org.uk/emc/product/1642/smpc#gref. Accessed January 23, 2023.
- US-Food and Drug Administration. Prescribing information of misoprostol 200 microgram tablet. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19268slr037.pdf. Accessed January 23, 2023.
- European Medicines Agency. Summary of product characteristic of misoprostol 200 microgram tablet. Available from: https://www.ema.europa.eu/en/documents/outside-eu-product-information/hemoprostol-product-information_en.pdf. Accessed February 13, 2023.
- Bettuzzi T, Ingen-Housz-Oro S, Purtillo CC, et al. Changing spectrum of suspected drugs of epidermal necrolysis: a World Health Organization pharmacovigilance database analysis from 1997–2020. J Am Acad Dermatol. 2021;85(6):1581–1584. doi:10.1016/j.jaad.2020.10.091
- Australian public assessment report for misoprostol; 2012. Available from: https://www.tga.gov.au/sites/default/files/auspar-misoprostol-121002.pdf. Access on February 13, 2023.
- Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96. doi:10.1001/archderm.1993.01680220104023
- Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–327. doi:10.1001/archderm.136.3.323
- Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019–1024. doi:10.1001/archderm.138.8.1019
- Piechota M, Banach M, Kopeć A, Rysz J, Narbutt J. Toxic epidermal necrolysis (Lyell’s syndrome): case report and review of the literature. Arch Med Sci. 2008;4(4):480–485.
- Buckingham R, ed. Martindale: the complete drug reference. London: Pharmaceutical Press. Available from: http://www.medicinescomplete.com.cmezproxy.chmeds.ac.nz/. Accessed February 10, 2023.
- University of Minnesota. Micromedex Help Guide. Available from: www.micromedexsolutions.com. Accessed February 10, 2023.
- Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2015. doi:10.1093/nar/gkv1075
- Madaan M, Puri M, Sharma R, Trivedi SS. Hypersensitivity reaction to misoprostol - a case report. IJCM. 2012;3(3). doi:10.4236/ijcm.2012.33044
- Lecorvaisier-Pieto C, Joly P, Thomine E, Tanasescu S, Noblet C, Lauret P. Toxic epidermal necrolysis after mifepristone/gemeprost-induced abortion. J Am Acad Dermatol. 1996;35(1):112. doi:10.1016/S0190-9622(96)90520-4
- Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96. doi:10.1097/00004630-200203000-00004
- Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–1350. doi:10.1038/nm.1884